Skip to main content
Premium Trial:

Request an Annual Quote

Ontera: Paul Marr, John Sperzel

Nanopore sensing and diagnostics company Ontera has appointed Paul Marr as its chief commercial officer and John Sperzel to its board of directors.

Marr has more than 22 years of in vitro diagnostics sales leadership experience that will be critical to the commercialization strategy for Ontera's NanoDetector device, the firm said. Prior to Ontera, he led the US laboratory sales team in providing high-throughput molecular diagnostic testing solutions at Hologic. Previously, he held various sales leadership roles at Beckman Coulter, Leica Biosystems, Siemens, and Ventana Medical Systems.

Sperzel, the president and CEO of T2 Biosystems, was previously president and CEO of Chembio Diagnostics. He was also president and CEO of ITC Medical and held executive leadership positions at Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory, and Boehringer Mannheim.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.